STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Co - TAK STOCK NEWS

Welcome to our dedicated news page for Takeda Pharmaceutical Co (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Takeda Pharmaceutical Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Takeda Pharmaceutical Co's position in the market.

News
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Rhea-AI Summary
FDA approves subcutaneous administration of ENTYVIO for ulcerative colitis maintenance therapy, providing patients and physicians with more flexibility. ENTYVIO SC demonstrated a statistically significant proportion of patients achieving clinical remission compared to placebo. Takeda does not expect a material impact on the full year forecast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
fda approval
-
News
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Rhea-AI Summary
Takeda receives approval for CUVITRU in Japan for patients with agammaglobulinemia or hypogammaglobulinemia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
News
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Rhea-AI Summary
Takeda's NDA resubmission for TAK-721 accepted by FDA for review, expects decision in H1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
clinical trial
News
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
Rhea-AI Summary
Takeda announces five new partnerships to its Global CSR Program, bringing total contributions to JPY 24.2 billion (Approx. USD 167.5 million) across 29 long-term partnerships. Takeda's workforce participated in the selection process. The new partnerships aim to reach 25.2 million people in 92 countries by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
partnership
-
News
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Rhea-AI Summary
Takeda's applications for subcutaneous administration of ENTYVIO for Crohn's disease and ulcerative colitis are under FDA review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
clinical trial
-
News
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
Rhea-AI Summary
Takeda announces positive topline results for TAK-279 in psoriatic arthritis, plans to initiate Phase 3 study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
clinical trial
News
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
Rhea-AI Summary
ImmunoGen enters exclusive collaboration with Takeda to develop and commercialize ELAHERE in Japan, receiving $34 million upfront and milestone payments, as well as double-digit royalties on future net sales in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
News
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.78%
Tags
earnings
-
News
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
earnings
News
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
Rhea-AI Summary
Takeda terminates development of narcolepsy treatment due to hepatotoxicity; oral orexin receptor 2 agonist shows positive results in improving wakefulness and reducing cataplexy rates compared to placebo
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
clinical trial
Stock TAK logo
Takeda Pharmaceutical Co

NYSE:TAK

TAK Rankings

#295 Ranked by Market Cap
#1877 Ranked by Stock Gains
#681 Ranked by Dividends

TAK Stock Data

42.46B
1.55B
0%
2.67%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Japan
Chuo Ku

About TAK

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.